7LLL: Deganutti G, Liang YL, Zhang X, Khoshouei M, Clydesdale L, Belousoff MJ, Venugopal H, Truong TT, Glukhova A, Keller AN, Gregory KJ, Leach K, Christopoulos A, Danev R, Reynolds CA, Zhao P, Sexton PM, Wootten D
Animal studies show low acute toxicity, but human safety data remain limited,,
Disposition : Structure: Acylated peptide with a fatty diacid moiety extends half-life via albumin binding Half-life: ~6 days supports once-weekly dosing Administration: Subcutaneous injection Clinical Data Highlights : Weight Loss: Up to 24.2% body weight reduction in phase 2 trials, highest recorded among incretin-based therapies Glycemic Control: HbA1c reductions of 2.02.5% in type 2 diabetes patients Lipid Profile: Significant drops in triglycerides, LDL-C, and liver fat content Insulin Sensitivity: Improved HOMA-IR and fasting insulin levels Energy Expenditure: Increased basal metabolic rate and fat oxidation via glucagon receptor activation For a full breakdown of Retatrutide clinical trials and results you can click the link
Strain WD et al
Research shows that standard oral glutathione is often degraded by digestive tract enzymes, limiting its effectiveness as a supplement unless protected by advanced delivery systems